SMAD4 and neoplasm: SMAD4/DPC4 deficiency significantly increased tumour cell immunogenicity by promoting spontaneous DNA damage and stimulating STING-mediated type I interferon signalling, which contributed to the activation of type 1 conventional dendritic cells (cDC1) and subsequently CD8+ T cells for tumour control.